Syros Pharmaceuticals

Syros Pharmaceuticals, Inc. engages in the development of gene control therapies for cancer and diseases. Its product candidates include SY-1425, SY-2101, and SY-5609. The company was founded by Richard A. Young, Nathanael S. Gray, and James E. Bradner on November 9, 2011 and is headquartered in Cambridge, MA.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Syros Pharmaceuticals excels in heme programs and strategic collaborations

Syros Pharmaceuticals demonstrated strong performance in heme programs, financial resilience, and strategic collaborations, despite challenges in expenses and net losses.
The company's focus on upcoming catalysts and clinical program advancements presents opportunities for growth and innovation in the competitive biopharmaceutical landscape.
Navigating challenges in trial protocols and financial management, Syros Pharmaceuticals aims to leverage strengths in regulatory designations and partnerships for sustainable growth.

Syros Pharmaceuticals reports Q1 progress in key programs and trials

Syros Pharmaceuticals' Q1 2023 performance reflects ongoing investments in late-stage clinical programs amid revenue generation.
The company's focus on key therapeutic areas and proactive approach to trial protocols position it for potential clinical and regulatory milestones.
While facing challenges in financial performance and the need for clarity on trial-related matters, Syros Pharmaceuticals maintains a solid cash position and promising opportunities ahead.

Syros Pharmaceuticals reports Q2 progress in clinical trials and challenges

Syros Pharmaceuticals' Q2 performance reflects a focus on advancing innovative therapies for MDS and AML amid significant R&D investments.
The company faces challenges in managing financials, decision-making timelines, and balancing investments with revenue generation.
Opportunities lie in the potential of tamibarotene, strategic partnerships, and upcoming data readouts to drive future growth and value creation.

Syros Pharmaceuticals advances tamibarotene for hematologic malignancies under new CEO

Syros Pharmaceuticals is strategically advancing tamibarotene for hematologic malignancies under new leadership, with a strong financial performance in the third quarter. While facing challenges in meeting efficacy data expectations, the company has opportunities to address unmet needs in AML and MDS, positioning itself for growth.

Syros Pharmaceuticals reports positive trial results and secures $45M financing

Syros Pharmaceuticals showcased strong performance in clinical trials and financial management in Q4 2023.
While facing challenges in regulatory aspects and profitability, the company is well-positioned for growth.
Opportunities lie in upcoming trial data, product launches, and strategic initiatives for revenue expansion.
Overall, Syros Pharmaceuticals remains optimistic about its future prospects and market positioning.

Syros Pharmaceuticals advances tamibarotene with FDA Fast Track Designation

Syros Pharmaceuticals showcased progress in clinical development programs, particularly with tamibarotene, and secured FDA Fast Track Designation for AML treatment. Despite no revenue in Q1 2024, the company's financial position remains stable with $108.3 million in cash and extended financial flexibility. Challenges include revenue impact from terminated agreements and the need to navigate market competition.

Syros Pharmaceuticals reports Q2 loss, eyes market expansion opportunities

Syros Pharmaceuticals showcased progress on tamibarotene trials with positive results in MDS and AML.
Financial performance in Q2 2024 reflected a net loss but maintained solid cash reserves for operations.
Analyst inquiries and executive insights highlighted strategic focus on pivotal studies and commercialization plans.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that it plans to host a three-part key opinion leader (KOL) webcast series on its portfolio of investigational targeted therapies in hematology. The series will consist of presentations from Syros leaders, as well as KOLs, who will review recent progress for SY-1425 in newly diagnosed higher-risk myelodysplastic syndrome (MDS) and

Syros to Host Key Opinion Leader Webcast Series on Targeted Hematology Portfolio

Syros Pharmaceuticals (SYRS) CEO Nancy Simonian on Q1 2021 Results - Earnings Call Transcript

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today reported financial results for the quarter ended March 31, 2021, and provided an update on recent accomplishments and upcoming events. “We continue to make substantial progress toward our vision of building Syros into a fully integrated company, with leading portfolios in targeted hematology and selective CDK inhibition and a robust gene co

Syros Reports First Quarter 2021 Financial Results and Highlights Key Accomplishments and Upcoming Milestones

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that it will host a live conference call and webcast at 8:30 a.m. ET on Thursday, May 6, 2021 to report its first quarter 2021 financial results and provide a corporate update. To access the live conference call, please dial 866-595-4538 (domestic) or 636-812-6496 (international), and refer to conference ID 5770919. A webcast of t

Syros to Report First Quarter 2021 Financial Results on Thursday May 6, 2021

It has been 10 months since we last looked at a developmental concern named Syros Pharmaceuticals and we promised we would keep an eye on developments.

Revisiting Syros Pharmaceuticals

Syros Pharmaceuticals, Inc. (SYRS) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Syros Pharmaceuticals, Inc. (SYRS) Stock Jumps 7.2%: Will It Continue to Soar?

Organovo Hlds

Catherine Wood ( Trades , Portfolio )'s ARK Investment Management has revealed a large reduction in the Organovo Holdings Inc. (NASDAQ:ONVO) position alongside a small reduction in the Syros Pharmaceuticals Inc. (NASDAQ:SYRS) position according to GuruFocus' Real-Time Picks, a Premium feature.

Catherine Wood's ARK Investment Slashes Organovo Holding

Syros Pharmaceuticals, Inc. (SYRS) CEO Nancy Simonian on Q4 2020 Results - Earnings Call Transcript

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today reported financial results for the quarter and full year ended December 31, 2020, and provided an update on recent accomplishments and upcoming events. “2021 promises to be a pivotal year for Syros,” said Nancy Simonian, M.D., Chief Executive Officer of Syros. “We moved our lead program into our first registration-enabling study and continu

Syros Reports Fourth Quarter and Full Year 2020 Financial Results and Highlights Key Accomplishments and Upcoming Milestones

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that it will host a live conference call and webcast at 8:30 a.m. ET on Thursday, March 4, 2021 to report its fourth quarter and full year 2020 financial results and provide a corporate update. To access the live conference call, please dial 866-595-4538 (domestic) or 636-812-6496 (international), and refer to conference ID 447246

Syros to Report Fourth Quarter and Full Year 2020 Financial Results on Thursday, March 4, 2021

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ: SYRS), a leader in the development of medicines that control the expression of genes, announced today that it has priced an underwritten public offering of 5,400,000 shares of common stock at a public offering price of $14.00 per share, which would result in gross proceeds of approximately $75.6 million, before underwriting discounts and commissions. The proceeds of the offering are expected to be used to fund the development of

Syros Announces Pricing of $75.6 Million Public Offering of Common Stock

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, announced today that it is offering to sell shares of its common stock in an underwritten public offering. The proceeds of the offering are expected to be used to fund the development of Syros' ongoing clinical and preclinical programs, and for working capital and other general corporate purposes. All of the shares in the offering are to be sold

Syros Announces Proposed Offering of Common Stock

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today outlined its strategic priorities and expected upcoming milestones. “Syros is rapidly accelerating toward becoming a commercial-stage company through three strategic priorities: advancing franchises in targeted hematology and selective CDK inhibition, as well as leveraging a robust gene control discovery engine to fuel our long-term growth,

Syros Announces Strategic Priorities and Expected Milestones

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Conference date in details should read: Thursday, January 14 (instead of Thursday, January 7) The updated release reads: SYROS TO PRESENT AT 39TH ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that its Chief Executive Officer, Nancy Simonian, M.D., will present a corporate overview at the virtual 39th Annual J.P. Morgan Healthcare Confe

CORRECTING and REPLACING Syros to Present at 39th Annual J.P. Morgan Healthcare Conference

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that its Chief Executive Officer, Nancy Simonian, M.D., will present a corporate overview at the virtual 39th Annual J.P. Morgan Healthcare Conference. Details are as follows: 39th Annual J.P. Morgan Healthcare Conference: Date: Thursday, January 7 Time: 2:50 p.m. ET A live webcast of the presentation will be available on the Inve

Syros to Present at 39th Annual J.P. Morgan Healthcare Conference

Syros Pharmaceuticals doubled its stock price in 2020. Syros recently acquired SY-2101 from Orsenix.

Syros Pharmaceuticals After The Orsenix Deal

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, announced today that it has closed a previously announced private financing with a group of institutional accredited investors led by Bain Capital Life Sciences, with participation from new and existing investors, including Ally Bridge Group, Omega Funds, OrbiMed Advisors, EcoR1 Capital, and Samsara BioCapital. In this financing, Syros sold an ag

Syros Closes $90.5 Million Strategic Financing

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that it has acquired from Orsenix, LLC (Orsenix) all of its assets related to SY-2101, formerly known as ORH-2014, a novel oral form of arsenic trioxide (ATO). SY-2101 represents a strategic opportunity to leverage Syros' expertise and capabilities to advance its growing footprint in hematologic disorders, with a targeted clinical

Syros Acquires Clinical-Stage Drug Candidate for Acute Promyelocytic Leukemia, Expanding Its Pipeline of Targeted Therapies for Hematologic Malignancies

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced new clinical data from its Phase 2 trial evaluating SY-1425, its first-in-class selective retinoic acid receptor alpha (RARα) agonist, in combination with azacitidine in two acute myeloid leukemia (AML) patient populations. The data is being presented today in oral presentations at the 62nd American Society of Hematology (ASH) Ann

Syros Presents New Data From Phase 2 Clinical Trial of SY-1425 and Announces Plans to Initiate Registration-Enabling Trial in MDS and Randomized Phase 2 Trial in AML

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that its Chief Executive Officer, Nancy Simonian, M.D., will participate in a pre-recorded fireside chat as part of the Piper Sandler 32nd Annual Virtual Healthcare Conference. Management will also be available for one-on-one meetings on Tuesday, December 1, 2020. The fireside chat will be available for on-demand viewing on the In

Syros Pharmaceuticals to Present at Piper Sandler 32nd Annual Virtual Healthcare Conference

Syros Pharmaceuticals' (SYRS) CEO Nancy Simonian on Q3 2020 Results - Earnings Call Transcript

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today reported financial results for the quarter ended September 30, 2020, and provided an update on recent accomplishments and upcoming events. “We are making great progress on the three pillars underlying our corporate strategy: advancing SY-1425 in RARA-positive patients, building on our leadership in CDK7 inhibition, and continuing to invest

Syros Pharmaceuticals Reports Third Quarter 2020 Financial Results and Highlights Key Accomplishments and Upcoming Milestones

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that it will present new clinical data from its fully enrolled, ongoing Phase 2 trial of SY-1425, its first-in-class oral selective retinoic acid receptor alpha (RARα) agonist, at the 62nd American Society of Hematology (ASH) Annual Meeting, taking place virtually December 5-8, 2020. The oral presentations will include data on SY-

Syros to Present New Data from Phase 2 Clinical Trial of SY-1425 in Oral Presentations at 62nd ASH Annual Meeting

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that it will host a live conference call and webcast at 4:30 p.m. ET on Thursday, November 5, 2020 to report its third quarter 2020 financial results and provide a corporate update. To access the live conference call, please dial 866-595-4538 (domestic) or 636-812-6496 (international), and refer to conference ID 1088286. A webcast

Syros to Report Third Quarter 2020 Financial Results on Thursday, November 5, 2020

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced initial safety, pharmacokinetics (PK) and pharmacodynamics (PD) data from the ongoing dose-escalation portion of its Phase 1 clinical trial of SY-5609 in patients with select solid tumors. SY-5609 is a highly selective and potent oral cyclin-dependent kinase 7 (CDK7) inhibitor. These early data demonstrate proof of mechanism in pa

News for Syros Pharmaceuticals Stock (SYRS)